« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence …
| Brand Name: | Afinitor |
| Generic Name: | everolimus |
| Code Name: | RAD001 |
| Company: | Novartis |
| FDA Clinical Phase: | 1/2 |
Description:
Afinitor was approved by the FDA in March 2009 for the …
| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and …
| Brand Name: | |
| Generic Name: | |
| Code Name: | BT-062 |
| Company: | Biotest |
| FDA Clinical Phase: | 1/2 |
Description:
BT-062 (news articles) …
| Brand Name: | |
| Generic Name: | milatuzumab |
| Code Name: | |
| Company: | Immunomedics, Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials, …
| Brand Name: | ImMucin |
| Generic Name: | |
| Code Name: | |
| Company: | Vaxil BioTherapeutics |
| FDA Clinical Phase: | 1/2 |
Description:
ImMucin is a vaccine designed to stimulate the patient’s own …